Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies James W Dear, FRCP, Joanna I Clarke, BSc, Ben Francis, PhD, Lowri Allen, MBChB, Jonathan Wraight, MD, Jasmine Shen, MBChB, Prof Paul I Dargan, FRCP, David Wood, MD, Jamie Cooper, MD, Prof Simon H L Thomas, MD, Andrea L Jorgensen, PhD, Prof Munir Pirmohamed, FRCP, Prof B Kevin Park, PhD, Daniel J Antoine, PhD The Lancet Gastroenterology & Hepatology Volume 3, Issue 2, Pages 104-113 (February 2018) DOI: 10.1016/S2468-1253(17)30266-2 Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND 4.0 license Terms and Conditions
Figure Study profile Summary of the patient outcome pathways for all patients prospectively recruited to the (A) derivation (MAPP) and (B) validation (BIOPAR) cohorts. ALT=alanine aminotransferase. INR=international normalised ratio. The Lancet Gastroenterology & Hepatology 2018 3, 104-113DOI: (10.1016/S2468-1253(17)30266-2) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND 4.0 license Terms and Conditions